Dicliptera chinensis (L.) Juss., is an herb known for its anti-inflammatory and anti-oxidant properties. In the previous studies, the chemical composition of the polysaccharide from Dicliptera chinensis (L.) Juss. (DCP) has been characterized as consisting of DCP₁ and DCP₂, of which DCP₂ has hepatoprotective effects. The study examined the hepatoprotective potential of DCP₂ against alpha-naphthyl isothiocyanate (ANIT)-induced cholestatic liver disease (CLD). In this study, RNA sequencing identified key research pathways involving bile acid metabolism, oxidative stress, and inflammation. Furthermore, qRT-PCR and Western blot analyses were conducted to further characterize these pathways. Additionally, the study included in vitro experiments with HepG2 cells to further investigate the effects of DCP₂ on bile acid metabolism. In summary, the protective effect of DCP₂ on the liver was reflected in alleviating the inflammatory response and oxidative stress, regulating the metabolism of bile acids, and mitigating liver damage caused by bile acids. This study further elucidated the hepatoprotective effects of DCP₂ by examining its ability to counteract ANIT-induced CLD, suggesting that DCP₂ is a promising biomacromolecule for hepatoprotection.

2024-02-01·Science of The Total Environment

Metagenomic insights into the diversity of 2,4-dichlorophenol degraders and the cooperation patterns in a bacterial consortium

Article

作者: Xu, Chuangchuang ; Han, Guomin ; Ma, Lu ; Niu, Qingfeng ; Hu, Shunli ; Huang, Junwei ; Xie, Yanghe

2,4-Dichlorophenol, which is largely employed in herbicides and industrial production, is frequently detected in ecosystems and poses risks to human health and environmental safety. Microbial communities are thought to perform better than individual strains in the complete degradation of organic contaminants. However, the synergistic degradation mechanisms of the microbial consortia involved in 2,4-dichlorophenol degradation are still not widely understood. In this study, a bacterial consortium named DCP-2 that is capable of degrading 2,4-dichlorophenol was obtained. Metagenomic analysis, cultivation-dependent functional verification, and co-occurrence network analysis were combined to reveal the primary 2,4-dichlorophenol degraders and the cooperation patterns in the consortium DCP-2. Metagenomic analysis showed that Pseudomonas, Achromobacter, and Pigmentiphaga were the primary degraders for the complete degradation of 2,4-dichlorophenol. Thirty-nine phylogenetically diverse bacterial genera, such as Brucella, Acinetobacter, Aeromonas, Allochromatium and Bosea, were identified as keystone taxa for 2,4-dichlorophenol degradation by keystone taxa analysis of the co-occurrence networks. In addition, a stable synthetic consortium of isolates from DCP-2 was constructed, consisting of Pseudomonas sp. DD-13 and Brucella sp. FZ-1; this synthetic consortium showed superior degradation capability for 2,4-dichlorophenol in both mineral salt medium and wastewater compared with monoculture. The findings provide valuable insights into the practical bioremediation of 2,4-dichlorophenol-contaminated sites.

2018-05-01·Asian-Australasian Journal of Animal Sciences3区 · 农林科学

Effect of wheat bran and dried carrot pomace addition on quality characteristics of chicken sausage

3区 · 农林科学

ArticleOA

作者: Islam, Rayees Ul ; Pathera, Ashok K ; Sharma, Diwakar P ; Yadav, Sanjay ; Malik, Ashok K

OBJECTIVEEffect of addition of wheat bran (WB) and dried carrot pomace (DCP) on sensory, textural, colour, physico-chemical and nutritional characteristics of chicken sausage were evaluated.METHODSWB and DCP were used as a source of dietary fibre at 3%, 6%, and 9% level individually. Different quality attributes of sausages were estimated. One product from each source with very good sensory acceptability was selected to analyze dietary fibre content and shelf life under refrigerated storage.RESULTSSensory acceptability of 3% fibre enriched sausage was comparable with control and a further increase in fibre level resulted in a decrease in sensory acceptability. Fibre enriched sausages were significantly harder and less cohesive than control sausage. Significant increase in gumminess and chewiness was observed at 6% level in WB treated sausages and 9% level in DCP treated sausages. Moisture content decreased significantly in all treated sausages, protein content decreased significantly in DCP-2 and DCP-3 sausages while fat content decreased in all WB and DCP-3 treated sausages in comparison to control. The fibre enriched sausage had significantly higher dietary fibre and lower cholesterol content. Cooking yield and emulsion stability increased in treated sausages and a significant difference was noticed at 6% level in both types of sausages. pH of WB treated sausages was significantly higher and DCP treated sausage significantly lower in comparison to control.CONCLUSIONThe results of present study indicate that fibre enriched chicken sausage with moderate acceptability can be developed by incorporating WB and DCP each up to 9% level. Chicken sausage with very good acceptability, higher dietary fibre content and storability up to 15 days at refrigerated temperature can be developed by incorporating WB and DCP at 6% level each.

项与 DCP-00X 相关的新闻（医药）

2023-03-30

·GlobeNewswire-Health Care

Mendus presents an update on the use of its DCOne platform to source high-quality NK cell therapies at the 8th Annual Innate Killer Summit

DCONE-DRIVEN EXPANSION OF MEMORY NK CELLS BUILDS THE BASIS FOR NOVEL PROPRIETARY PIPELINE PROGRAM Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that it will present additional data highlighting the use of the company’s proprietary DCOne platform for the ex vivo expansion of NK cells today at the 8th Annual Innate Killer Cell Summit in La Jolla, San Diego, CA. Natural Killer (NK) cells are part of the innate immune system and form a first line of defense against infections and tumor cells. Memory NK cells are associated with improved tumor cell killing and significantly reduced relapse rates in bone marrow-transplanted leukemia patients. Memory NK cells therefore hold great therapeutic promise in the treatment of hematological cancers and potentially other tumor types. “Significant efforts in the NK field have been made to develop superior and reliable expansion methods for NK cells with optimal therapeutic efficacy, including efforts to improve memory phenotype. The NK cell research at Mendus has focused on using our proprietary DCOne platform to improve NK cell quality and specifically on memory NK cells,” said Erik Manting, PhD, Chief Executive Officer of Mendus. “The DCOne platform provides for an off-the-shelf source of cells which combine cancer cell and dendritic cell biology. Another important aspect of the DCOne cell line is that it is supported by an extensive regulatory dossier and has demonstrated an excellent safety profile in multiple clinical trials.” The data presented today and at SITC 2022 demonstrate that DCOne cells drive strong expansion of memory NK cells, which subsequently can be used in different therapeutic applications. The presence of activating ligands on the cell surface of DCOne-derived mature dendritic cells provide a mechanistic rationale for the observed expansion of memory NK cells with well-characterized molecular signatures. The Innate Killer Summit is an industry conference focused on improving patient care by advancing the understanding and enhancing of innate immune cell therapies. On March 30, 3.15pm PST (00:15 CET) Mendus’ CEO Erik Manting, PhD, will hold a presentation titled “Developing Expansion Protocols to Enrich for Memory Phenotypes to Produce Quality over Quantity in Final NK Cell Therapy Products” as part of the Clinical Scale Manufacturing track. During the conference, Dr Manting also chaired a panel discussion titled “Sharing a Vision of the Future for Commercial Scale Manufacturing of Innate Immune Cells” on March 29. FOR MORE INFORMATION, PLEASE CONTACT: Erik MantingChief Executive OfficerE-mail: ir@mendus.com INVESTOR RELATIONSCorey DavisLifeSci Advisors, LLCTelephone: + 1 212-915-2577E-mail: cdavis@lifesciadvisors.com MEDIA RELATIONS Mario BrkuljValency CommunicationsTelephone: +49 160 9352 9951E-mail: mbrkulj@valencycomms.eu ABOUT MENDUS AB (PUBL) Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. http://www.mendus.com/ Attachment 230330_Mendus_Innate Killer Summit_ENG

免疫疗法细胞疗法临床研究AACR会议

100 项与 DCP-00X 相关的药物交易

登录后查看更多信息